{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:14Z","timestamp":1740144074187,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40268-022-00399-y","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T18:02:43Z","timestamp":1661018563000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study"],"prefix":"10.1007","volume":"22","author":[{"given":"Maki","family":"Umemiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-5913","authenticated-orcid":false,"given":"Yoshihide","family":"Inayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-446X","authenticated-orcid":false,"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Gou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"399_CR1","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/sj.bjc.6602076","volume":"91","author":"H Tsuda","year":"2004","unstructured":"Tsuda H, Hashiguchi Y, Nishimura S, Miyama M, Nakata S, Kawamura N, et al. Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer. 2004;91:1032\u20137.","journal-title":"Br J Cancer"},{"key":"399_CR2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3892\/ol.2012.853","volume":"4","author":"S Machida","year":"2012","unstructured":"Machida S, Sato T, Fujiwara H, Saga Y, Takei Y, Taneichi A, et al. Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma. Oncol Lett. 2012;4:1017\u201322.","journal-title":"Oncol Lett"},{"key":"399_CR3","first-page":"61","volume":"10","author":"M Takano","year":"2017","unstructured":"Takano M, Sugiyama T. UGT1A1 polymorphisms in cancer: impact on irinotecan treatment. Pharmgenomics Pers Med. 2017;10:61\u20138.","journal-title":"Pharmgenomics Pers Med."},{"key":"399_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104398","volume":"148","author":"C Bailly","year":"2019","unstructured":"Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148: 104398.","journal-title":"Pharmacol Res"},{"key":"399_CR5","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1111\/ajco.13028","volume":"14","author":"Y Yang","year":"2018","unstructured":"Yang Y, Zhou M, Hu M, Cui Y, Zhong Q, Liang L, et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: a meta-analysis. Asia Pac J Clin Oncol. 2018;14:e479\u201389.","journal-title":"Asia Pac J Clin Oncol"},{"key":"399_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2407-4-36","volume":"4","author":"T Kuehr","year":"2004","unstructured":"Kuehr T, Ruff P, Rapoport BL, Falk S, Daniel F, Jacobs C, et al. Phase I\/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer. 2004;4:36.","journal-title":"BMC Cancer"},{"key":"399_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40880-018-0304-1","volume":"38","author":"JH Kim","year":"2018","unstructured":"Kim JH, Lee SC, Oh SY, Song SY, Lee N, Nam EM, et al. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. Cancer Commun (Lond). 2018;38:32.","journal-title":"Cancer Commun (Lond)."},{"key":"399_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/bcp.13574","volume":"84","author":"P Riera","year":"2018","unstructured":"Riera P, Salazar J, Virgili AC, Tobena M, Sebio A, Gallano P, et al. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity. Br J Clin Pharmacol. 2018;84:1389\u201392.","journal-title":"Br J Clin Pharmacol"},{"key":"399_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jjco\/hyi219","volume":"36","author":"E Takaoka","year":"2006","unstructured":"Takaoka E, Kawai K, Ando S, Shimazui T, Akaza H. Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer. Jpn J Clin Oncol. 2006;36:60\u20133.","journal-title":"Jpn J Clin Oncol"},{"key":"399_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3748\/wjg.v23.i1.42","volume":"23","author":"FG Rodrigues","year":"2017","unstructured":"Rodrigues FG, Dasilva G, Wexner SD. Neutropenic enterocolitis. World J Gastroenterol. 2017;23:42\u20137.","journal-title":"World J Gastroenterol"},{"key":"399_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00280-017-3344-3","volume":"80","author":"X Zhang","year":"2017","unstructured":"Zhang X, Yin JF, Zhang J, Kong SJ, Zhang HY, Chen XM. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Cancer Chemother Pharmacol. 2017;80:135\u201349.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"399_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/jcm7090246","volume":"7","author":"H Urushiyama","year":"2018","unstructured":"Urushiyama H, Jo T, Yasunaga H, Michihata N, Yamana H, Matsui H, et al. Effect of Hangeshashin-To (Japanese Herbal Medicine Tj-14) on tolerability of irinotecan: propensity score and instrumental variable analyses. J Clin Med. 2018;7(9):246.","journal-title":"J Clin Med"},{"key":"399_CR13","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood.V89.7.2303","volume":"89","author":"M MacManus","year":"1997","unstructured":"MacManus M, Lamborn K, Khan W, Varghese A, Graef L, Knox S. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood. 1997;89:2303\u201310.","journal-title":"Blood"},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2020.09.007","volume":"141","author":"EC Hulshof","year":"2020","unstructured":"Hulshof EC, Deenen MJ, Guchelaar HJ, Gelderblom H. Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: ready for prime time. Eur J Cancer. 2020;141:9\u201320.","journal-title":"Eur J Cancer"},{"key":"399_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40121-017-0146-1","volume":"6","author":"KV Rolston","year":"2017","unstructured":"Rolston KV. Infections in cancer patients with solid tumors: a review. Infect Dis Ther. 2017;6:69\u201383.","journal-title":"Infect Dis Ther"},{"key":"399_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.gtc.2010.08.004","volume":"39","author":"MA Shafi","year":"2010","unstructured":"Shafi MA, Bresalier RS. The gastrointestinal complications of oncologic therapy. Gastroenterol Clin N Am. 2010;39:629\u201347.","journal-title":"Gastroenterol Clin N Am"},{"key":"399_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11894-014-0383-3","volume":"16","author":"AH Harb","year":"2014","unstructured":"Harb AH, Abou Fadel C, Sharara AI. Radiation enteritis. Curr Gastroenterol Rep. 2014;16:383.","journal-title":"Curr Gastroenterol Rep"},{"key":"399_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","volume":"31","author":"P Mauch","year":"1995","unstructured":"Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1319\u201339.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"399_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.currproblcancer.2015.07.010","volume":"39","author":"RS Prabhu","year":"2015","unstructured":"Prabhu RS, Cassidy RJ, Landry JC. Radiation therapy and neutropenia. Curr Probl Cancer. 2015;39:292\u20136.","journal-title":"Curr Probl Cancer"},{"key":"399_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","volume":"393","author":"PA Cohen","year":"2019","unstructured":"Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. The Lancet. 2019;393:169\u201382.","journal-title":"The Lancet"},{"key":"399_CR21","doi-asserted-by":"publisher","first-page":"6285","DOI":"10.2147\/CMAR.S195989","volume":"11","author":"T Kumar","year":"2019","unstructured":"Kumar T, Schernberg A, Busato F, Laurans M, Fumagalli I, Dumas I, et al. Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation. Cancer Manag Res. 2019;11:6285\u201397.","journal-title":"Cancer Manag Res"},{"key":"399_CR22","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1097\/IGC.0000000000000292","volume":"24","author":"B Hui","year":"2014","unstructured":"Hui B, Zhang Y, Shi F, Wang J, Wang T, Wang J, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy. Int J Gynecol Cancer. 2014;24:1648\u201352.","journal-title":"Int J Gynecol Cancer"},{"key":"399_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85\u201391.","journal-title":"N Engl J Med"},{"key":"399_CR24","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609\u201318.","journal-title":"N Engl J Med"},{"key":"399_CR25","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1200\/JCO.2006.09.4532","volume":"25","author":"PG Rose","year":"2007","unstructured":"Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:2804\u201310.","journal-title":"J Clin Oncol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00399-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-022-00399-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-022-00399-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:29:44Z","timestamp":1669415384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-022-00399-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s40268-022-00399-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"26 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Maki Umemiya, Yoshihide Inayama, Eiji Nakatani, Kenta Ito, Mitsuru Tsuji, Teruki Yoshida, Sae Yu, Rei Gou, Naoki Horikawa, Hirohiko Tani, and Kenzo Kosaka declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The minimal datasets that are required to replicate the outcomes of the study will be made available by the corresponding author upon reasonable request. The data are not publicly available due to privacy or ethical restrictions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The Institutional Review Board of Shizuoka General\u00a0Hospital approved this study (reference number: SGHIRB#2021015).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The need to obtain written informed consent from patients was waived because of the retrospective design of this study. For the representative case, consent for publication was obtained from a family member of the patient.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Conceptualization and design: MU, YI, NH, HT and KK. Investigation: MU, YI, TY, SY, MT and RG. Data curation: MU, YI, EN and KI. Writing of the original draft: MU, YI, EN and KI. Review and editing: TY, SY, MT, RG, NH, HT and KK. Supervision: YI and KK.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}